ETF:MEAR - Daily Stock Analysis for MiMedx Group Inc

MiMedx Group Inc. Daily Stock Analysis

Stock Information

Open 50.00	Close 49.96	High 50.00	Low 49.96	Previous Close 50.03	Daily Price Gain -0.06
YTD High 50.78	YTD High Date Jan 3, 2017	YTD Low 49.62	YTD Low Date Jan 4, 2017	YTD Price Change 0.16	YTD Gain 0.32%
52 Week High 51.94	52 Week High Date Dec 19, 2016	52 Week Low 49.47	52 Week Low Date Oct 4, 2016	52 Week Price Change 0.27	52 Week Gain 0.54%

Company Information

Stock Symbol MEAR	Exchange NasdaqCM	Company URL http://www.mimedx.com	Company Phone 678-384-6720
CEO Parker H. Petit	Headquarters Georgia	Business Address 1775 W OAK COMMONS COURT, NE, MARIETTA, GA 30062
Sector f healthcare. In addition, it provides OrthoFlo, an amniotic fluid derived allograft for homologous use. Further, the company's proprietary platforms include Physio, a unique bone grafting material for maximizing bone forming potential and a demineralized bone matrix; and AlloBurn, a skin product for burns. Additionally, it offers CollaFix, a collagen fiber technology developed with the company's patented cross-linking polymers, designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues in order to augment their repair. The CollaFix is the biological, biodegradable, and biomimetic technology that matches human tendon in strength and stiffness. The company primarily provides regenerative medicine specialties in wound care, and surgical, sports medicine, and orthopedics with spinal procedures. It sells its products through direct sales force, and independent stocking distributors and representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. was formerly known as MiMedx, Inc. and changed its name to MiMedx Group, Inc. in February 2008. The company is headquartered in Marietta, Georgia.	Industry Category Health Services	Industry Group Medical Appliances & Equipment	CIK 0001376339
About MiMedx Group, Inc. develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues, and human skin and bone.
Description MiMedx Group, Inc. develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues, and human skin and bone. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are tissue technologies processed from human amniotic membrane derived from donated placentas. The company processes the human amniotic membrane utilizing its proprietary PURION Process to produce an implant. It also supplies amniotic tissue comprising approximately 500,000 allografts for applications in the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. In addition, it provides OrthoFlo, an amniotic fluid derived allograft for homologous use. Further, the company's proprietary platforms include Physio, a unique bone grafting material for maximizing bone forming potential and a demineralized bone matrix; and AlloBurn, a skin product for burns. Additionally, it offers CollaFix, a collagen fiber technology developed with the company's patented cross-linking polymers, designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues in order to augment their repair. The CollaFix is the biological, biodegradable, and biomimetic technology that matches human tendon in strength and stiffness. The company primarily provides regenerative medicine specialties in wound care, and surgical, sports medicine, and orthopedics with spinal procedures. It sells its products through direct sales force, and independent stocking distributors and representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. was formerly known as MiMedx, Inc. and changed its name to MiMedx Group, Inc. in February 2008. The company is headquartered in Marietta, Georgia.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

Daily Stock Analysis, MEAR, MiMedx Group Inc, priceseries

Legal Information

Useful Links

Contact Us